Avidity Partners Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.18M | Buy |
+232,000
| New | +$2.18M | 0.43% | 47 |
|
|
2024
Q3 | – | Sell |
-170,000
| Closed | -$3.8M | – | 95 |
|
|
2024
Q2 | $3.8M | Buy |
+170,000
| New | +$3.8M | 0.16% | 75 |
|
|
2024
Q1 | – | Sell |
-447,434
| Closed | -$13.6M | – | 97 |
|
|
2023
Q4 | $13.6M | Buy |
447,434
+68,334
| +18% | +$2.08M | 0.5% | 53 |
|
|
2023
Q3 | $12M | Sell |
379,100
-16,755
| -4% | -$530K | 0.48% | 61 |
|
|
2023
Q2 | $16.1M | Sell |
395,855
-21,145
| -5% | -$862K | 0.56% | 60 |
|
|
2023
Q1 | $15.5M | Sell |
417,000
-221,200
| -35% | -$8.24M | 0.52% | 59 |
|
|
2022
Q4 | $22.3M | Sell |
638,200
-360,900
| -36% | -$12.6M | 0.48% | 47 |
|
|
2022
Q3 | $55.9M | Sell |
999,100
-126,094
| -11% | -$7.06M | 1.14% | 31 |
|
|
2022
Q2 | $58.2M | Buy |
1,125,194
+735,119
| +188% | +$38M | 1.34% | 25 |
|
|
2022
Q1 | $28.3M | Buy |
+390,075
| New | +$28.3M | 0.59% | 44 |
|
|
2021
Q4 | – | Sell |
-251,000
| Closed | -$33.7M | – | 107 |
|
|
2021
Q3 | $33.7M | Sell |
251,000
-129,000
| -34% | -$17.3M | 0.75% | 43 |
|
|
2021
Q2 | $61.5M | Buy |
+380,000
| New | +$61.5M | 1.66% | 21 |
|
|
2021
Q1 | – | Sell |
-303,000
| Closed | -$16.5M | – | 113 |
|
|
2020
Q4 | $16.5M | Buy |
+303,000
| New | +$16.5M | 0.54% | 52 |
|
|
2020
Q3 | – | Sell |
-418,178
| Closed | -$8.79M | – | 79 |
|
|
2020
Q2 | $8.79M | Buy |
+418,178
| New | +$8.79M | 0.56% | 47 |
|